905587-41-9

Usage

Uses

Used in Research Applications:
5-FPMA is used as a research chemical for studying the effects of substituted amphetamines on the central nervous system. Its unique pharmacological properties make it a valuable tool for understanding the mechanisms of action and potential therapeutic applications of related compounds.
Used in Controlled Substances Regulation:
Due to its potential for abuse and adverse effects, such as increased heart rate, anxiety, and potential neurotoxicity at higher doses, 5-FPMA is classified as a controlled substance in many countries. It is illegal to manufacture, possess, or distribute without proper authorization, making it a subject of regulatory control to prevent misuse and protect public health.

Upstream product

• 38275-55-7 5- fluoropyrimidine-2-carbonitrile 
• 905587-43-1 1-(5-fluoropyrimidin-2-yl)ethan-1-ol 
• 905587-44-2 1-(5-fluoropyrimidin-2-yl)ethan-1-one 
• 905587-42-0 2-(1-azidoethyl)-5-fluoropyrimidine 

Relevant academic research and scientific papers

Use of Immobilized Amine Transaminase from Vibrio fluvialis under Flow Conditions for the Synthesis of (S)-1-(5-Fluoropyrimidin-2-yl)-ethanamine

We report on the covalent immobilization of the (S)-selective amine transaminase from Vibrio fluvialis (Vf-ATA) and its use in the synthesis of (S)-1-(5-fluoropyrimidin-2-yl)-ethanamine, a key intermediate of the JAK2 kinase inhibitor AZD1480. Immobilized Vf-ATA on glyoxyl-agarose (activity recovery: 30 %) was used in a packed-bed reactor to set-up a continuous flow biotransformation coupled with a straightforward in-line purification to circumvent the 2-step process described in literature for the batch reaction. The newly developed biotransformation was run in a homogeneous system including dimethyl carbonate as a green co-solvent. Optically pure (S)-1-(5-fluoropyrimidin-2-yl)-ethanamine (ee >99 %) was isolated in 35 % yield.

Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway

The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs. Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor. 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials.

4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.